K. Foucar, B. Falini, D. Catovsky, and H. Stein, Hairy cell leukemia, Classification of Tumours of Haematopietic and Lymphoid Tissues, 2008.

S. H. Swerdlow, E. Campo, and S. A. Pileri, The 2016 revision of the World Health Organization classification of lymphoid neoplasms, Blood, vol.127, issue.20, pp.2375-90, 2016.
URL : https://hal.archives-ouvertes.fr/hal-01800015

T. Robak, Hairy-cell leukemia variant: recent view on diagnosis, biology and treatment, Cancer Treat Rev, vol.37, issue.1, pp.3-10, 2011.

A. Traverse-glehen, L. Baseggio, and E. C. Bauchu, Splenic red pulp lymphoma with numerous basophilic villous lymphocytes: a distinct clinicopathologic and molecular entity?, Blood, vol.111, issue.4, pp.2253-2260, 2008.

E. Matutes, R. Morilla, K. Owusu-ankomah, A. Houliham, P. Meeus et al., Proposal for a scoring system to distinguish HCL from B-cell disorders with hairy or villous lymphocytes, Leuk Lymphoma, vol.14, issue.1, pp.57-61, 1994.

M. R. Grever, A. Wahab, O. Andritsos, and L. A. , Consensus guidelines for the diagnosis and management of patients with classic hairy cell leukemia, Blood, vol.129, issue.5, pp.553-560, 2017.
URL : https://hal.archives-ouvertes.fr/hal-02194198

M. Piris, K. Foucar, M. Mollejo, E. Campo, and B. Falini, Splenic B-cell lymphoma/leukemia unclassifiable, WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, 2008.

F. Forconi, E. Sozzi, and E. Cencini, Hairy cell leukemias with unmutated IGHV genes define the minor subset refractory to single-agent cladribine and with more aggressive behavior, Blood, vol.114, issue.21, pp.4696-4702, 2009.

N. Poret, Q. Fu, and S. Guihard, CD38 in hairy cell leukemia is a marker of poor prognosis and a new target for therapy, Cancer Res, vol.75, issue.18, p.5167, 2015.

E. Arons, T. Suntum, M. Stetler-stevenson, and R. J. Kreitman, VH4-341 hairy cell leukemia, a new variant with poor prognosis despite standard therapy, Blood, vol.114, issue.21, pp.4687-4695, 2009.

L. Xi, E. Arons, and W. Navarro, Both variant and IGHV4-34-expressing hairy cell leukemia lack the BRAF V600E mutation

, Blood, vol.119, issue.14, pp.3330-3332, 2012.

E. Tiacci, V. Trifonov, and G. Schiavoni, BRAF mutations in hairy-cell leukemia, N Engl J Med, vol.364, issue.24, pp.2305-2315, 2011.

B. Jebaraj, D. Kienle, and A. B?-uhler, BRAF mutations in chronic lymphocytic leukemia, Leuk Lymphoma, vol.54, issue.6, pp.1177-1182, 2013.

S. Tschernitz, L. Flossbach, M. Bonengel, S. Roth, and A. Rosenwald, Geissinger E. Alternative BRAF mutations in BRAF V600E-negative hairy cell leukaemias, Brit J Haematol, vol.165, issue.4, pp.529-562, 2014.

D. M. Hyman, I. Puzanov, and V. Subbiah, Vemurafenib in multiple nonmelanoma cancers with BRAF V600 mutations, N Engl J Med, vol.373, issue.8, pp.726-736, 2015.

E. Tiacci, J. H. Park, D. Carolis, and L. , Targeting mutant BRAF in relapsed or refractory hairy-cell leukemia, N Engl J Med, vol.373, issue.18, pp.1733-1747, 2015.

B. Falini, M. P. Martelli, and E. Tiacci, BRAF V600E mutation in hairy cell leukemia: from bench to bedside, Blood, vol.128, issue.15, pp.1918-1927, 2016.

S. S. Chung, E. Kim, and J. H. Park, Hematopoietic stem cell origin of BRAFV600E mutations in hairy cell leukemia, Sci Transl Med, 2014.

, , vol.6, pp.238-71

S. Loghavi and J. D. Khoury, Langerhans cell histiocytosis in a patient with hairy cell leukemia: a tale of divergence, Blood, vol.129, issue.11, pp.1563-1563, 2017.

P. Milne, V. Bigley, and C. M. Bacon, Hematopoietic origin of Langerhans cell histiocytosis and Erdheim Chester disease in adults, Blood, vol.130, issue.2, pp.167-175, 2017.

J. J. Waterfall, E. Arons, and R. L. Walker, High prevalence of MAP2K1 mutations in variant and IGHV4-34-expressing hairy-cell leukemias, Nat Genet, vol.46, issue.1, pp.8-10, 2014.

S. Dietrich, J. H?-ullein, and S. Lee, Recurrent CDKN1B (p27) mutations in hairy cell leukemia, Blood, vol.126, issue.8, pp.1005-1008, 2015.

B. H. Durham, B. Getta, and S. Dietrich, Genomic analysis of hairy cell leukemia identifies novel recurrent genetic alterations, Blood, vol.130, issue.14, pp.1644-1648, 2017.

L. Jallades, L. Baseggio, and P. Sujobert, Exome sequencing identifies recurrent BCOR alterations and the absence of KLF2, TNFAIP3 and MYD88 mutations in splenic diffuse red pulp small B-cell lymphoma, Haematologica, vol.102, issue.10, pp.17558-1766, 2017.
URL : https://hal.archives-ouvertes.fr/hal-01583112

E. Tiacci, G. Schiavoni, and F. Forconi, Simple genetic diagnosis of hairy cell leukemia by sensitive detection of the BRAF-V600E mutation, Blood, vol.119, issue.1, pp.192-195, 2012.

S. Curiel-olmo, R. Mond-ejar, and C. Almaraz, Splenic diffuse red pulp small B-cell lymphoma displays increased expression of cyclin D3 and recurrent CCND3 mutations, Blood, vol.129, issue.8, pp.1042-1045, 2017.

A. Traverse-glehen, A. Verney, and S. Gazzo, Splenic diffuse red pulp lymphoma has a distinct pattern of somatic mutations amongst B-cell malignancies, Leuk Lymphoma, vol.58, issue.3, pp.666-675, 2017.
URL : https://hal.archives-ouvertes.fr/hal-01795706

M. J. Kiel, T. Velusamy, and B. L. Betz, Whole-genome sequencing identifies recurrent somatic NOTCH2 mutations in splenic marginal zone lymphoma, J Exp Med, vol.209, issue.9, pp.1553-1565, 2012.

R. Piva, S. Deaglio, and R. Fama, The Kr? uppel-like factor 2 transcription factor gene is recurrently mutated in splenic marginal zone lymphoma, Leukemia, vol.29, issue.2, pp.503-507, 2015.

A. Traverse-glehen, L. Baseggio, G. Salles, B. Coiffier, P. Felman et al., Splenic diffuse red pulp small-B cell lymphoma: toward the emergence of a new lymphoma entity, Discov Medicine, vol.13, issue.71, pp.253-265, 2012.

V. Divino, S. Karve, and A. Gaughan, Characteristics and treatment patterns among US patients with hairy cell leukemia: a retrospective claims analysis, J Comp Eff Res, vol.6, issue.6, pp.497-508, 2017.

T. Robak, E. Matutes, D. Catovsky, P. L. Zinzani, and C. Buske, ESMO Guidelines Committee. Hairy cell leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up, Ann Oncol, vol.26, issue.5, pp.100-107, 2015.

F. Garnache-ottou, M. O. Chandesris, and L. Lhermitte, Peripheral blood 8 colour flow cytometry monitoring of hairy cell leukaemia allows detection of high-risk patients, Brit J Haematol, vol.166, issue.1, pp.50-59, 2014.

A. U. Akarca, V. H. Shende, and A. D. Ramsay, BRAF V600E mutationspecific antibody, a sensitive diagnostic marker revealing minimal residual disease in hairy cell leukaemia, Br J Haematol, vol.162, issue.6, pp.848-851, 2013.

M. Else, C. E. Dearden, and D. Catovsky, Long-term follow-up after purine analogue therapy in hairy cell leukaemia, Best Pract Res Clin Haematol, vol.28, issue.4, pp.217-229, 2015.

D. Chihara, H. Kantarjian, and S. O'brien, Long-term durable remission by cladribine followed by rituximab in patients with hairy cell leukaemia: update of a phase II trial, Br J Haematol, vol.174, issue.5, pp.760-766, 2016.

M. Leclerc, F. Suarez, and . No?-el-m-p, Rituximab therapy for hairy cell leukemia: a retrospective study of 41 cases, Ann Hematol, vol.94, issue.1, pp.89-95, 2015.

J. Bohn, E. Willenbacher, and M. Steurer, Obinutuzumab in multidrugresistant hairy cell leukemia, Ann Hematol, vol.95, issue.2, pp.351-352, 2016.

E. Cornet, A. Delmer, and P. Feugier, Recommendations of the SFH (French Society of Haematology) for the diagnosis, treatment and follow-up of hairy cell leukaemia, Ann Hematol, vol.93, issue.12, pp.1977-1983, 2014.
URL : https://hal.archives-ouvertes.fr/hal-01699263

S. Dietrich, H. Glimm, M. Andrulis, K. V. , C. Ho et al., BRAF inhibition in refractory hairy-cell leukemia, N Engl J Med, vol.366, issue.21, pp.2038-2040, 2012.

S. Dietrich, A. Pircher, and V. Endris, BRAF inhibition in hairy cell leukemia with low dose vemurafenib, Blood, vol.127, issue.23, pp.2847-55, 2016.

M. K. Callahan, R. Rampal, and J. J. Harding, Progression of RAS-Mutant Leukemia during RAF Inhibitor Treatment, N Engl J Med, vol.367, issue.24, pp.2316-2321, 2012.

N. Yaktapour, F. Meiss, and J. Mastroianni, BRAF inhibitor-associated ERK activation drives development of chronic lymphocytic leukemia, J Clin Invest, vol.124, issue.11, pp.5074-5084, 2014.

R. J. Kreitman, W. H. Wilson, and J. D. White, Phase I trial of recombinant immunotoxin anti-Tac(Fv)-PE38 (LMB-2) in patients with hematologic malignancies, J Clin Oncol, vol.18, issue.8, pp.1622-1636, 2000.

J. C. Byrd, R. R. Furman, and S. E. Coutre, Three-year follow-up of treatment-naïve and previously treated patients with CLL and SLL receiving single-agent ibrutinib, Blood, vol.125, issue.16, pp.2497-2506, 2015.

A. Sarvaria, Z. Topp, and A. Saven, Current therapy and new directions in the treatment of hairy cell leukemia: a review, JAMA Oncol, vol.2, issue.1, pp.123-129, 2016.

M. Burotto, M. Stetler-stevenson, E. Arons, H. Zhou, and W. Wilson, Kreitman RJ. Bendamustine and rituximab in relapsed and refractory hairy cell leukemia, Clin Cancer Res, vol.19, issue.22, pp.6313-6321, 2013.

A. S. Gerrie, L. N. Zypchen, and J. M. Connors, Fludarabine and rituximab for relapsed or refractory hairy cell leukemia, Blood, vol.119, issue.9, 2012.

R. J. Kreitman, W. Wilson, and K. R. Calvo, Cladribine with immediate rituximab for the treatment of patients with variant hairy cell leukemia, Clin Cancer Res, vol.19, issue.24, pp.6873-6881, 2013.

J. P. Bohn, D. Wanner, and M. Steurer, Ibrutinib for relapsed refractory hairy cell leukemia variant, Leuk Lymphoma, vol.58, issue.5, pp.1224-1226, 2017.

R. Schmitz, R. M. Young, and M. Ceribelli, Burkitt lymphoma pathogenesis and therapeutic targets from structural and functional genomics, Nature, vol.490, issue.7418, pp.116-120, 2012.

E. Cornet, C. Tomowiak, and A. Tanguy-schmidt, How to cite this article: Troussard X, Cornet E. Hairy cell leukemia 2018: Update on diagnosis, risk-stratification, and treatment, Br J Haematol, vol.166, issue.3, pp.1382-1390, 2014.